NCT03713905View on ClinicalTrials.gov

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

293

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Advanced Solid Tumors
Interventions
DRUG

GLS-010

Recombinant Human Anti-PD-1 Monoclonal Antibody

Trial Locations (1)

Unknown

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
lead

Guangzhou Gloria Biosciences Co., Ltd.

INDUSTRY

NCT03713905 - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter